Public Employees Retirement System of Ohio Has $31,000 Stake in MacroGenics, Inc. $MGNX

Public Employees Retirement System of Ohio grew its holdings in MacroGenics, Inc. (NASDAQ:MGNX) by 261.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,982 shares of the biopharmaceutical company’s stock after purchasing an additional 18,800 shares during the period. Public Employees Retirement System of Ohio’s holdings in MacroGenics were worth $31,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. State of Wyoming acquired a new position in MacroGenics in the first quarter worth approximately $28,000. American Century Companies Inc. increased its holdings in MacroGenics by 236.6% in the first quarter. American Century Companies Inc. now owns 39,525 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 27,782 shares during the last quarter. Deutsche Bank AG increased its holdings in MacroGenics by 3,803.2% in the first quarter. Deutsche Bank AG now owns 51,093 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 49,784 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in MacroGenics by 19.7% in the first quarter. Exchange Traded Concepts LLC now owns 58,434 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 9,611 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in MacroGenics by 90.0% in the first quarter. Invesco Ltd. now owns 68,377 shares of the biopharmaceutical company’s stock worth $87,000 after buying an additional 32,398 shares during the last quarter. Institutional investors and hedge funds own 96.89% of the company’s stock.

MacroGenics Price Performance

Shares of MGNX stock opened at $1.78 on Thursday. The stock has a market cap of $112.51 million, a P/E ratio of -3.12 and a beta of 1.61. MacroGenics, Inc. has a one year low of $0.99 and a one year high of $5.10. The stock has a fifty day moving average price of $1.67 and a 200 day moving average price of $1.54.

MacroGenics (NASDAQ:MGNX) last issued its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.02. The firm had revenue of $22.24 million during the quarter, compared to analysts’ expectations of $28.06 million. MacroGenics had a negative return on equity of 40.24% and a negative net margin of 21.99%. Equities research analysts anticipate that MacroGenics, Inc. will post -1.06 EPS for the current year.

Insider Buying and Selling

In other news, Director William K. Heiden bought 50,500 shares of MacroGenics stock in a transaction that occurred on Tuesday, August 19th. The stock was purchased at an average cost of $1.52 per share, with a total value of $76,760.00. Following the completion of the transaction, the director directly owned 61,500 shares in the company, valued at $93,480. This trade represents a 459.09% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.00% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Barclays assumed coverage on MacroGenics in a report on Wednesday, September 17th. They issued an “overweight” rating and a $3.00 price objective on the stock. Leerink Partners dropped their price objective on MacroGenics from $8.00 to $5.00 and set an “outperform” rating on the stock in a report on Friday, August 15th. Wall Street Zen cut MacroGenics from a “hold” rating to a “sell” rating in a research report on Saturday, August 2nd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MacroGenics in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $3.60.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.